IMC Chicago’s Nektar Therapeutics NKTR Stock Holding History

IMC Chicago’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Buy	22,412 +6,051	+37%	+$443K	﹤0.01%	3326
2026 Q1	$1.18M	Buy	+16,361	New	+$932K	﹤0.01%	3112

Other funds holding NKTR

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IMC Chicago's NKTR Position: Q2 2026 in Review

IMC Chicago increased its Nektar Therapeutics (NKTR) stake by 37% in Q2 2026, buying an estimated $443K and bringing the position to 22,412 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

IMC Chicago first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

IMC Chicago held 22,412 shares of Nektar Therapeutics worth $1.56M as of Q2 2026.
IMC Chicago bought 6,051 Nektar Therapeutics shares in Q2 2026, an estimated $443K.
Nektar Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #3326 holding.
IMC Chicago first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
147 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.